218 related articles for article (PubMed ID: 24386929)
1. Neoadjuvant chemotherapy in breast cancer significantly reduces number of yielded lymph nodes by axillary dissection.
Erbes T; Orlowska-Volk M; Zur Hausen A; Rücker G; Mayer S; Voigt M; Farthmann J; Iborra S; Hirschfeld M; Meyer PT; Gitsch G; Stickeler E
BMC Cancer; 2014 Jan; 14():4. PubMed ID: 24386929
[TBL] [Abstract][Full Text] [Related]
2. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
3. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
[TBL] [Abstract][Full Text] [Related]
4. The effect of internal mammary lymph node biopsy on the therapeutic decision and survival of patients with breast cancer.
Ozmen V; Ozcinar B; Bozdogan A; Eralp Y; Yavuz E; Dincer M
Eur J Surg Oncol; 2015 Oct; 41(10):1368-72. PubMed ID: 26210653
[TBL] [Abstract][Full Text] [Related]
5. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.
Pernas S; Gil M; Benítez A; Bajen MT; Climent F; Pla MJ; Benito E; Guma A; Gutierrez C; Pisa A; Urruticoechea A; Pérez J; Gil Gil M
Ann Surg Oncol; 2010 Mar; 17(3):772-7. PubMed ID: 20183912
[TBL] [Abstract][Full Text] [Related]
6. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.
Avril A; Le Bouëdec G; Lorimier G; Classe JM; Tunon-de-Lara C; Giard S; MacGrogan G; Debled M; Mathoulin-Pélissier S; Mauriac L;
Eur J Surg Oncol; 2011 Jul; 37(7):563-70. PubMed ID: 21665421
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of sentinel lymph node micrometastases in patients with invasive breast carcinoma.
Cipolla C; Graceffa G; La Mendola R; Fricano S; Fricano M; Vieni S
Ann Ital Chir; 2015; 86():497-502. PubMed ID: 26898168
[TBL] [Abstract][Full Text] [Related]
8. Factors Influencing Management and Outcome in Patients with Occult Breast Cancer with Axillary Lymph Node Involvement: Analysis of the National Cancer Database.
Hessler LK; Molitoris JK; Rosenblatt PY; Bellavance EC; Nichols EM; Tkaczuk KHR; Feigenberg SJ; Bentzen SM; Kesmodel SB
Ann Surg Oncol; 2017 Oct; 24(10):2907-2914. PubMed ID: 28766198
[TBL] [Abstract][Full Text] [Related]
9. Local radiotherapy alone following neoadjuvant chemotherapy and surgery in combined clinical stage II and III breast cancer.
White R; Dinneen T; Makris A
Radiat Oncol; 2016 Jul; 11():93. PubMed ID: 27457764
[TBL] [Abstract][Full Text] [Related]
10. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer with axillary node metastasis: A survey of clinical practice.
Lee SB; Yu JH; Park H; Kim HJ; Park SH; Chae BJ; Youn HJ; Jung SY; Kim EK; Jung YS; Son BH
Asian J Surg; 2019 Jan; 42(1):314-319. PubMed ID: 30049563
[TBL] [Abstract][Full Text] [Related]
11. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
[TBL] [Abstract][Full Text] [Related]
12. Discordance of intraoperative frozen section analysis with definitive histology of sentinel lymph nodes in breast cancer surgery: complementary axillary lymph node dissection is irrelevant for subsequent systemic therapy.
Geertsema D; Gobardhan PD; Madsen EV; Albregts M; van Gorp J; de Hooge P; van Dalen T
Ann Surg Oncol; 2010 Oct; 17(10):2690-5. PubMed ID: 20422461
[TBL] [Abstract][Full Text] [Related]
13. Axillary lymph node dissection is not obligatory in breast cancer patients with biopsy-proven axillary lymph node metastasis.
Yoo TK; Kang BJ; Kim SH; Song BJ; Ahn J; Park WC; Chae BJ
Breast Cancer Res Treat; 2020 Jun; 181(2):403-409. PubMed ID: 32328848
[TBL] [Abstract][Full Text] [Related]
14. Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence.
Kilbride KE; Lee MC; Nees AV; Cimmino VM; Diehl KM; Sabel MS; Hayes DF; Schott AF; Kleer CG; Chang AE; Newman LA
Ann Surg Oncol; 2008 Nov; 15(11):3252-8. PubMed ID: 18784961
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series.
Grossmith S; Nguyen A; Hu J; Plichta JK; Nakhlis F; Cutone L; Dominici L; Golshan M; Duggan M; Carter K; Rhei E; Barbie T; Calvillo K; Nimbkar S; Bellon J; Wong J; Punglia R; Barry W; King TA
Ann Surg Oncol; 2018 Nov; 25(12):3527-3534. PubMed ID: 29868979
[TBL] [Abstract][Full Text] [Related]
16. Improving the Accuracy of Axillary Lymph Node Surgery in Breast Cancer with Ultrasound-Guided Wire Localization of Biopsy Proven Metastatic Lymph Nodes.
Plecha D; Bai S; Patterson H; Thompson C; Shenk R
Ann Surg Oncol; 2015 Dec; 22(13):4241-6. PubMed ID: 25814365
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.
Milgrom S; Cody H; Tan L; Morrow M; Pesce C; Setton J; Rogers K; Arnold B; Eaton A; Catalano J; McCormick B; Powell S; Ho A
Ann Surg Oncol; 2012 Nov; 19(12):3762-70. PubMed ID: 22576064
[TBL] [Abstract][Full Text] [Related]
18. Long-term prognosis in breast cancer is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status.
Zetterlund L; Celebioglu F; Hatschek T; Frisell J; de Boniface J
Br J Surg; 2021 May; 108(5):583-589. PubMed ID: 34043772
[TBL] [Abstract][Full Text] [Related]
19. Patterns in the Use of Axillary Operations for Patients with Node-Positive Breast Cancer After Neoadjuvant Chemotherapy: A National Cancer Database (NCDB) Analysis.
Srour MK; Tseng J; Luu M; Alban RF; Giuliano AE; Chung A
Ann Surg Oncol; 2019 Oct; 26(10):3305-3311. PubMed ID: 31342364
[TBL] [Abstract][Full Text] [Related]
20. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
Reitsamer R; Peintinger F; Rettenbacher L; Prokop E
J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
